Single-ingredient ordinary thiamine,
does it really help with Pain relief in painful diabetic peripheral neuropathy?
research showsThe documented search and currently accessible material did not identify an eligible result isolating the added effect of ordinary oral thiamine on diabetic neuropathic pain. The current published judgment is ? with no numerical score. This means that direct evidence for the exact claim was not verified, not that the treatment has no effect.
ads claimAdvertising and mechanistic claims were not used as grade bonuses or direct clinical evidence.
Four separate assessment dimensions
| Effect direction and size | The documented search and currently accessible material did not identify an eligible result isolating the added effect of ordinary oral thiamine on diabetic neuropathic pain. The current published judgment is ? with no numerical score. This means that direct evidence for the exact claim was not verified, not that the treatment has no effect. |
|---|---|
| Evidence certainty | The rubric’s ? rule is applied within this page’s molecule, route, population and endpoint. The structural flag no_human_study is scoped to no eligible human result identified in the documented search, not a claim that no study exists anywhere. It is not based on access failure alone: search and screening records and combination exclusions are also supplied. Repeated refutation (RX) was not established, so F is not assigned. |
| Applicability | Adults with painful diabetic peripheral neuropathy; distinct from confirmed B1 (thiamine)-deficiency neuropathy |
| Safety | Safety is marked unknown because eligible efficacy and safety results for this exact monotherapy were not verified. Adverse events or tolerability of other B-vitamin combinations are not transferred to ordinary thiamine alone. |
Not official GRADE or treatment-success probability; ? has no score.
Useful facts when choosing a product
- The question concerns adding ordinary thiamine alone by mouth. Exact salt, product, dose, duration and baseline B1-deficiency assessment are unconfirmed. A comparison that also changes B6 is not direct evidence for this single-ingredient question.
Chamgap Semantic Classification Code
Permanent code issued
S.thiamine.oral.diabetic-peripheral-neuropathy-pain.reduce.placebo-or-no-additionSupplements > Single-ingredient ordinary thiamine > Oral > Painful diabetic peripheral neuropathy pain > Reduction claim > Placebo or no addition
Technically bound to the current-value claim boundary fixed by ChatGPT. Unconfirmed dose, duration, study details, and evidence grade remain in verdict fields and revision history rather than the permanent semantic code. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Single-ingredient ordinary thiamine (vitamin B1) |
| Source or part used | Synthetic/fermentation/other production origin unconfirmed; plant-part classification not applicable |
| Formulation or processing | Question: ordinary thiamine alone by mouth; salt and formulation in an eligible outcome study unconfirmed |
| Route | Oral (page question; see observed_evidence for study-route verification) |
| Dose | Actual dose in an eligible monotherapy outcome study unconfirmed |
| Duration | Treatment and follow-up duration in an eligible monotherapy study unconfirmed |
| Population | Adults with painful diabetic peripheral neuropathy; distinct from confirmed B1 (thiamine)-deficiency neuropathy |
| Effect or condition | Pain relief in painful diabetic peripheral neuropathy |
| Primary endpoint | Patient-reported neuropathic pain; specific scale in an eligible study unconfirmed |
| Comparator | Question: placebo/no addition on matched usual care; actual eligible comparative results unconfirmed |
| Duplicate-detection key | ordinary-thiamine-single|oral|dose-unconfirmed|duration-unconfirmed|painful-diabetic-peripheral-neuropathy|patient-reported-pain-scale-unconfirmed|placebo-or-no-addition-question |
What the research actually shows
A registry candidate exists, but the official result body was not obtained. The human Abbas–Swai study changed both B1 and B6 doses, so it cannot isolate the effect of B1 alone. A registry entry, a combination result and a pain result for ordinary thiamine monotherapy are distinct.
Why this is classified as ?
The rubric’s ? rule is applied within this page’s molecule, route, population and endpoint. The structural flag no_human_study is scoped to no eligible human result identified in the documented search, not a claim that no study exists anywhere. It is not based on access failure alone: search and screening records and combination exclusions are also supplied. Repeated refutation (RX) was not established, so F is not assigned.
Counterpoint. Related research was not erased as nonexistent. Existing verdict 544 on benfotiamine and broad B1 nerve-function verdict 162 are related, but molecule or population–endpoint boundaries differ; they are not treated as the same completed claim.
Rejudgment record. The documented search and currently accessible material did not identify an eligible result isolating the added effect of ordinary oral thiamine on diabetic neuropathic pain. The current published judgment is ? with no numerical score. This means that direct evidence for the exact claim was not verified, not that the treatment has no effect. — The rubric’s ? rule is applied within this page’s molecule, route, population and endpoint. The structural flag no_human_study is scoped to no eligible human result identified in the documented search, not a claim that no study exists anywhere. It is not based on access failure alone: search and screening records and combination exclusions are also supplied. Repeated refutation (RX) was not established, so F is not assigned.
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests Case application: Defines the question, not an observed eligible trial; unused scoring axes remain null |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
Molecular details, dose, duration and comparator results in an eligible monotherapy trial unconfirmed Registry body inaccessible; existence of results not settled Native databases worldwide were not exhaustively searched; the current judgment is published with that limitation.
Search scope and limitations. tasks/R01-002/search_log.json
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy | Registry candidate; result body not verified | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Registry title concerns painful diabetic peripheral neuropathy; result body and actual scale unverified | The official registry URL was reached, but its result body was not readable. A trial candidate is not the same as an obtained outcome result. | Registry candidate; result body not verified |
| Abbas and Swai — thiamine plus pyridoxine in symptomatic diabetic neuropathy (1997) | Excluded: different or confounded intervention | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Diabetic neuropathy symptoms in a B1+B6 dose comparison | The neuropathy trial compared B1 25 mg plus B6 50 mg with B1 1 mg plus B6 1 mg. Because B6 also changed, it does not isolate thiamine (B1). | Excluded: different or confounded intervention |
Receipt — 2 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-15 · current_value_initial_publication — An unverified registry status was not filled in as completed, withdrawn or null; benfotiamine and B1+B6 results were not assigned to thiamine alone.
Cite this verdict
[Chamgap] Single-ingredient ordinary thiamine (vitamin B1) × Pain relief in painful diabetic peripheral neuropathy — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/oral-thiamine-diabetic-neuropathy-pain/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.